VTX2735 not checked
Zomagen Biosciences Ltd. · LY5625574
FollowEvery change as it happens, and a Monday email
Trials
1 active
2 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Recurrent Pericarditis
- Main trialPhase 2
- “This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP). Cohort A will include approximately 10 participants and will consist of the following: * A 30-day Screening Period (to see if a participant qualifies for the study) * A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A * A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A * An 11-week Once Daily Treatment Period (if a participant meets criteria for this…”In the company’s words, NCT06836232 on ClinicalTrials.gov
- Other names
- LY5625574
Other drugs for Recurrent Pericarditis
- KPL-387Kiniksa Pharmaceuticals International, plc · Phase 2/3
- CardiolRxCardiol Therapeutics Inc. · Phase 3
- GoflikiceptR-Pharm International, LLC · Phase 3
Coming up1
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Oct 2027 | An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis | |
| Phase 2Completed | 6 Mar 2024 | A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026